Skip to main content
Bladder CancerCG Oncology· 6 min read· in Health

CG Oncology Bladder Cancer Immunotherapy Slashes Recurrence Risk by 68 Percent

A late-stage trial of the oncolytic immunotherapy cretostimogene grenadenorepvec demonstrated a 68 percent reduction in disease recurrence for patients with early-stage bladder tumors. The highly anticipated results significantly outperformed analyst expectations and showcased a pristine safety profile with zero severe adverse events.

By Jun Zhao

Share this story

Listen

On November 16, 2026, CG Oncology announced that its investigational oncolytic immunotherapy, cretostimogene grenadenorepvec, reduced the risk of bladder cancer recurrence by 68 percent in a late-stage clinical trial. The results mark a significant breakthrough. They offer new hope for a patient population that currently lacks approved post-surgical treatments.[1][5]

The Phase 3 PIVOT-006 registrational trial evaluated the therapy in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer. These patients had already undergone a complete transurethral resection to remove their visible tumors prior to receiving the experimental treatment.[3][6]

With a hazard ratio of 0.32, the data establish the modified virus as a highly effective adjuvant therapy. The trial results significantly exceeded the expectations of financial analysts, who had previously projected a clinically meaningful risk reduction of between 30 and 40 percent.[1][5]

"The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology," said Dr. Vijay Kasturi, the company's Chief Medical Officer. He noted that the data position the drug as the first therapeutic candidate to demonstrate a significant recurrence benefit in this specific pivotal setting.[6]

Unprecedented recurrence-free survival

The randomized, open-label PIVOT-006 trial enrolled 367 post-surgery patients across approximately 90 clinical sites in the United States and Canada. Participants were assigned to receive either adjuvant intravesical cretostimogene or standard surveillance, which is the current protocol following a complete tumor resection.[1][3]

After a median follow-up period of 17 months, calculated as of October 26, 2026, the trial successfully met its primary endpoint of recurrence-free survival. The 68 percent reduction in recurrence risk was highly statistically significant, yielding a p-value of less than 0.0001.[5][6]

The PIVOT-006 trial demonstrated a highly statistically significant recurrence benefit over standard surveillance.

The trial focused specifically on patients with Ta tumors, which are early-stage cancers found on the inner lining of the bladder that have not yet penetrated the deeper tissue. To qualify for the study, these high-grade tumors could not be larger than three centimeters.[1][6]

While the trial has not yet reached its median recurrence-free survival duration, the early data provide a clear indication of the drug's durability. The company confirmed that the therapy provided a recurrence-free survival benefit across both high-grade and low-grade patient subgroups.[1]

A dual-action viral therapy

Cretostimogene grenadenorepvec represents a novel approach to treating urologic oncology. The therapy is a genetically modified virus. It is administered directly into the bladder via a catheter, a localized delivery method designed to maximize exposure to the bladder lining.[1][3]

Once inside the bladder, the oncolytic virus employs a dual mechanism of action to combat the disease. It is specifically engineered to infect and kill the remaining tumor cells that were not removed during the initial surgical resection.[1]

Beyond its direct cell-killing capabilities, the modified virus is also designed to trigger a broader immune response. As the virus destroys the cancer cells, it stimulates the patient's own immune system to recognize and attack any lingering malignancy, helping to prevent future recurrences.[1]

The genetically modified virus is designed to kill tumor cells directly while triggering a broader immune response.

This localized, immune-stimulating approach offers a targeted alternative to systemic treatments. By confining the viral replication and immune activation primarily to the bladder, the therapy aims to eradicate residual disease without exposing the rest of the body to severe toxicity.[1][3]

Avoiding severe adverse events

Safety and tolerability remain critical hurdles in the development of new bladder cancer treatments, as severe local irritation often forces patients to abandon therapy. However, the safety data from the PIVOT-006 trial indicate that cretostimogene was generally well tolerated.[3][6]

Investigators reported that there were zero Grade 3 or higher treatment-related adverse events among the patients receiving the oncolytic immunotherapy. The side-effect profile remained highly favorable. It was consistent with the safety data reported in the company's previous clinical studies.[3][5]

Furthermore, the trial recorded no treatment-related discontinuations, meaning patients were able to complete their prescribed therapeutic regimen without experiencing debilitating toxicity. This high compliance rate is essential for achieving the long-term recurrence-free survival observed in the study.[1][6]

The absence of severe adverse events bolsters the drug's profile as a viable adjuvant option. For a patient population that currently relies on active surveillance, a treatment must offer a favorable risk-benefit ratio to justify intervention before a recurrence actually happens.[1][3]

Filling a critical treatment gap

Non-muscle invasive bladder cancer accounts for a significant majority of all newly diagnosed bladder cancer cases. While the initial surgical resection successfully removes the visible tumors, the disease is notorious for its exceptionally high rate of recurrence.[1][3]

Patients with intermediate-risk and high-grade Ta tumors face a constant threat of relapse. This requires frequent and invasive monitoring. Despite this high risk, CG Oncology notes that there are currently no FDA-approved adjuvant treatment options available for this specific patient population.[3][6]

Illustration: Patients with intermediate-risk bladder tumors currently rely on active surveillance and frequent monitoring due to a lack of approved therapies.

The company estimates that this underserved demographic includes approximately 50,000 patients in the United States alone. If approved, cretostimogene would become the first therapeutic intervention specifically indicated to delay or prevent the cancer from returning in these individuals.[1][6]

A successful approval in this intermediate-risk category would dramatically expand the drug's clinical utility. Financial analysts at TD Cowen noted that securing this indication would at least double the potential addressable market for the oncolytic immunotherapy.[1]

Accelerating regulatory submissions

Armed with the unprecedented PIVOT-006 data, CG Oncology is accelerating its regulatory strategy. The company announced plans to submit a biologics license application to the FDA for the intermediate-risk and high-grade Ta indication in the second quarter of 2027.[1][3]

This submission will follow a separate, broadened application for patients with BCG-unresponsive non-muscle invasive bladder cancer. Based on recent FDA feedback, the company is expanding that initial submission to include both carcinoma in situ and high-grade papillary-only disease.[3][6]

CG Oncology now expects to complete the broadened submission for the BCG-unresponsive indication by March 2027, moving ahead of its previously planned timeline. Securing approvals in both settings would establish the drug as a foundational treatment across multiple stages of the disease.[3][5]

The commercial implications of these dual indications are substantial. Industry analysts project that global peak sales for cretostimogene grenadenorepvec could reach $3.7 billion by 2035, driven by the sheer volume of patients lacking effective bladder-sparing alternatives.[1]

The company is accelerating its regulatory submissions to the FDA following the unprecedented Phase 3 results.

Preparing for commercialization

Rather than partnering with a larger pharmaceutical corporation, CG Oncology plans to commercialize the therapy itself within the United States. A company spokesperson confirmed that they have been building the necessary infrastructure for some time to support an independent launch.[1]

The company's medical affairs, market access, and commercial teams are already in place or currently being assembled. This independent commercialization strategy reflects the biotech firm's confidence in the drug's clinical profile and its potential rapid adoption by urologic oncologists.[1]

The full dataset from the PIVOT-006 trial is scheduled for a late-breaking podium presentation next month. Researchers will share the detailed findings at the Society of Urologic Oncology Annual Meeting in San Diego on December 2, 2026.[1][6]

As the urology community awaits the complete presentation, the topline results already signal a major shift in bladder cancer management. For tens of thousands of patients, this viral immunotherapy could soon provide a durable defense against a relentless disease.[1][3]

Key points

  1. The Phase 3 PIVOT-006 trial met its primary endpoint, cutting the likelihood of bladder cancer returning by 68 percent compared to standard surveillance.
  2. The viral therapy demonstrated an exceptionally clean safety profile, causing no severe treatment-related adverse events or patient discontinuations during the study.
  3. CG Oncology intends to file for FDA approval in the second quarter of 2027 to treat this specific intermediate-risk patient demographic.
  4. Financial analysts anticipate that securing this expanded indication could drive the drug's peak global sales to $3.7 billion over the next decade.

What we don’t know

  • The final median recurrence-free survival duration, as the clinical trial has not yet run long enough to reach that statistical threshold.
  • How the FDA will ultimately respond to the company's broadened submission for the BCG-unresponsive indication expected in March 2027.
  • Whether the localized immune response triggered by the virus will provide lifelong protection against recurrence or require eventual re-treatment.
Clinical Urologists 40%Biotech Analysts 35%Patient Advocacy Groups 25%
Clinical Urologists
Medical professionals focused on the practical benefits of the therapy's safety profile and efficacy.
Biotech Analysts
Financial and industry analysts evaluating the commercial potential of the drug's expanded indications.
Patient Advocacy Groups
Organizations representing bladder cancer patients who lack approved treatment options.

Perspectives this story doesn't cover

  • Health insurance providers
  • European regulatory authorities

Sources

Source coverage

6 outlets

3 viewpoints surfaced

Clinical Urologists 40%Biotech Analysts 35%Patient Advocacy Groups 25%
  1. [1]Endpoints NewsClinical Urologists

    CG Oncology's bladder cancer treatment beats expectations in Phase 3

    Read on Endpoints News →
  2. [2]MarketScreenerBiotech Analysts

    CG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial

    Read on MarketScreener →
  3. [3]Investing.comBiotech Analysts

    CG Oncology reports positive phase 3 trial results for bladder cancer

    Read on Investing.com →
  4. [4]TipRanksClinical Urologists

    CG Oncology Reports Positive Phase 3 Bladder Cancer Trial Results

    Read on TipRanks →
  5. [5]TradingViewBiotech Analysts

    CG Oncology Reports 68% Lower Recurrence Risk in Phase 3 PIVOT-006 Trial

    Read on TradingView →
  6. [6]StockTitanPatient Advocacy Groups

    CG Oncology: preliminary 68% recurrence risk reduction

    Read on StockTitan →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.